

18 Jun 2021 | News

QUOTED. 18 June 2021. Harith Rajagopalan.

by

Fractyl Health closed a \$100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.

“We’ve seen from the clinical work that we’ve done that Revita has the potential to be a ‘backbone’ therapy in type 2 diabetes and other metabolic diseases.” – Harith Rajagopalan, CEO, Fractyl Health

- Find out more: [Fractyl Adds \\$100M Investment To Address Root Causes Of Type 2 Diabetes](#)

[Click here](#) for a free trial of *Medtech Insight*